KLB and fatty liver disease: Data from experimental studies have shown that FGF-21, acting through on its receptor (FGFR1) on the cell membrane with β-Klotho as co-receptor, increases fatty acid β-oxidation and decreases de novo lipogenesis, thereby attenuating hepatic steatosis.